| 44.85 -0.69 (-1.52%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 53.33  |
1-year : | 62.29 |
| Resists | First : | 45.66 |
Second : | 53.33 |
| Pivot price | 43.98 |
|||
| Supports | First : | 42.94 |
Second : | 41.27 |
| MAs | MA(5) : | 44.22 |
MA(20) : | 43.64 |
| MA(100) : | 43.56 |
MA(250) : | 44.96  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 77.6 |
D(3) : | 63.4 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 49.91 | Low : | 40.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SNY ] has closed below upper band by 14.4%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.71 - 45.98 | 45.98 - 46.21 |
| Low: | 44.19 - 44.47 | 44.47 - 44.73 |
| Close: | 44.44 - 44.9 | 44.9 - 45.31 |
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Tue, 28 Jul 2026
Sanofi SA (SNY) Stock Up 3.5% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Tue, 28 Jul 2026
Sanofi (SNY) discloses $534M portfolio across 10 positions in latest 13F - Stock Titan
Mon, 27 Jul 2026
Sanofi (NASDAQ: SNY) ends amlitelimab in atopic dermatitis trials - Stock Titan
Fri, 24 Jul 2026
Earnings Preview: Sanofi to Report Financial Results Pre-market on July 30 - Moomoo
Fri, 24 Jul 2026
Sanofi (SNY) Holds Steady Near $43.35 as Range-Bound Trading Persists - MFI Overbought - po-news-eg.net
Fri, 24 Jul 2026
Sanofi Drops Dupixent Successor Candidate After Assessing Data - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 2,170 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 7,370 (K) |
| Shares Short P.Month | 6,430 (K) |
| EPS | 2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 15.9 % |
| Operating Margin | 20 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 6.5 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 14.33 |
| Sales Per Share | 19.81 |
| EBITDA (p.s.) | 5.36 |
| Qtrly Earnings Growth | -11.7 % |
| Operating Cash Flow | 10,340 (M) |
| Levered Free Cash Flow | 16,670 (M) |
| PE Ratio | 19.84 |
| PEG Ratio | 3.8 |
| Price to Book value | 0 |
| Price to Sales | 2.26 |
| Price to Cash Flow | 0 |
| Dividend | 2.42 |
| Forward Dividend | 0 |
| Dividend Yield | 5.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|